Dr. Bukavina on bladder and kidney cancer research to watch for at SUO 2023


Laura Bukavina, MD, MPH, offers a preview of noteworthy bladder and kidney cancer research to be presented at this year's Society of Urologic Oncology Annual Meeting.

In this video, Laura Bukavina, MD, MPH, outlines bladder and kidney cancer presentations to watch for at this year’s Society of Urologic Oncology Annual Meeting. Bukavina is an assistant professor of urologic oncology at University Hospitals Cleveland Medical Center, Case Western Reserve School of Medicine in Cleveland, Ohio. Specific presentations Bukavina highlighted include:

• Bladder Cancer Debate: Management of complete clinical response following neoadjuvant systemic therapy for muscle invasive bladder cancer (Moderator: James M. McKiernan, MD)

• Defining the biology of UTUC and how this shapes therapy (Bishoy M. Faltas, MD)

• Systemic therapy: choosing among neoadjuant/adjuvant approaches (Jean Hoffman-Censits, MD)

• Risk-stratification, biomarkers and surgical management of UTUC (Helen Y. Hougen, MD)

• Chemo-ablation and renal preservation is the future (Katie S. Murray, DO, MS, FACS)

• Trials in UTUC and unmet needs (Jennifer A. Linehan, MD)

• #47: Blood-based liquid biopsy in diagnosis, surveillance, and prognosis of patients with primary UTUC (Alireza Ghorefi, MD)

• #57: Neoadjuvant chemotherapy and radical nephroureterectomy (RNU) vs. RNU alone for upper tract urothelial carcinoma: a multi-institutional cohort analysis (ROBUUST Collaborative) (Nicholas Corsi, MD)

• #165: Oncologic Outcomes of Intravesical Therapy in the Management of Non-Muscle Invasive Bladder Cancer with Variant Histology (Zaeem Lone, MD)

• #163: Comparing white light versus blue light cystoscopy recurrence outcomes among non-muscle invasive bladder cancer patients in an equal access setting: a propensity scored matched analysis (Sanjay Das, MD)

• #146: Consistent performance of Bladder EpiCheck for NMIBC surveillance in the USA and European pivotal studies and in real world studies (Neil Fleshner, MD)

• #71: Value of B7-H3 Expression as a Predictor of Response to Neoadjuvant Chemotherapy in Urothelial Cell Carcinoma of Bladder (Reza Nadavizadesh, MD)

• #66: Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer (Kevin Chang, MD)

• #80: Aim high: epigenetic modulation and immune stimulation in bladder cancer (Elizabeth Koehne, MD)

• #6: SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer [NCT04510597] (Hyung Kim, MD)

• #7: Safety of partial and radical nephrectomy for complex locally advanced renal cell carcinoma after neo-adjuvant immune checkpoint inhibition (durvalumab +/- tremelimumab) (Joseph Zabell, MD)

• #13: Limited utility of quantitative thresholds on 99MTC-sestamibi SPECT/CT for distinguishing renal cell carcinoma from oncocytic renal masses (Robert S. Wang, MD)

• #103: Comprehensive Immunogenomic Evaluation of Patients Undergoing Consolidative Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Treated with Immune Checkpoint Blockade (Stephen Reese, MD)

Recent Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.